Envestnet Asset Management
NKTR icon

Envestnet Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Envestnet Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714K Sell
10,223
-660
-6% -$48.3K ﹤0.01% 3837
2026
Q1 		$783K Buy
10,883
+5,499
+102% +$313K ﹤0.01% 3616
2025
Q4 		$228K Sell
5,384
-4,702
-47% -$263K ﹤0.01% 4195
2025
Q3 		$574K Buy
+10,086
New +$334K ﹤0.01% 3665
2023
Q4 		– Sell
-1,137
Closed -$10.2K – 4126
2023
Q3 		$10.2K Sell
1,137
-3,090
-73% -$29.7K ﹤0.01% 3995
2023
Q2 		$36.5K Buy
+4,227
New +$45.1K ﹤0.01% 3898
2022
Q1 		– Sell
-954
Closed -$193K – 4016
2021
Q4 		$193K Sell
954
-17
-2% -$3.69K ﹤0.01% 3668
2021
Q3 		$262K Buy
971
+67
+7% +$16.1K ﹤0.01% 3364
2021
Q2 		$233K Sell
904
-210
-19% -$58.1K ﹤0.01% 3426
2021
Q1 		$334K Buy
1,114
+313
+39% +$97.4K ﹤0.01% 3079
2020
Q4 		$204K Buy
+801
New +$207K ﹤0.01% 3131
2019
Q3 		– Sell
-458
Closed -$244K – 3139
2019
Q2 		$244K Sell
458
-31
-6% -$15.5K ﹤0.01% 2796
2019
Q1 		$246K Sell
489
-27
-5% -$16K ﹤0.01% 2728
2018
Q4 		$254K Sell
516
-3,826
-88% -$2.31M ﹤0.01% 2527
2018
Q3 		$3.97M Buy
4,342
+4,276
+6,479% +$3.65M 0.01% 470
2018
Q2 		$47K Sell
66
-6
-8% -$6.92K ﹤0.01% 2226
2018
Q1 		$109K Buy
72
+15
+26% +$19.3K ﹤0.01% 1879
2017
Q4 		$51K Buy
+57
New +$33.7K ﹤0.01% 2312
2017
Q1 		– Sell
-5
Closed -$1K – 3148
2016
Q4 		$1K Buy
+5
New +$1.02K ﹤0.01% 3043

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's NKTR Position: Q2 2026 in Review

Envestnet Asset Management reduced its Nektar Therapeutics (NKTR) stake by 6.1% in Q2 2026, selling an estimated $48.3K and leaving 10,223 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

Envestnet Asset Management first reported a position in NKTR in Q4 2016 and has held it in 19 quarters since. The position peaked at $3.97M in Q3 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Envestnet Asset Management held 10,223 shares of Nektar Therapeutics worth $714K as of Q2 2026.
  • Envestnet Asset Management sold 660 Nektar Therapeutics shares in Q2 2026, an estimated $48.3K.
  • Nektar Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3837 holding.
  • Envestnet Asset Management first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 19 quarters since.
  • Envestnet Asset Management's Nektar Therapeutics position peaked at $3.97M in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.